Sign In
Buy BBI
$1.94
+0 (+0%)
At Close: Feb 07, 2023
Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting
04:49pm, Friday, 17'th Apr 2026
Findings support the ongoing Phase 1 clinical development of BBI-940, an oral, selective kinesin degrader, as a potential first-in-class therapy for select advanced or metastatic breast cancers Findin
Boundless Bio: An Underestimated Biotech With A First-In-Class EcDNA Targeted Kinesin Degrader
03:25am, Friday, 20'th Mar 2026
Boundless Bio offers a highly asymmetric risk/reward profile, trading at a $25M valuation with $107.6M in cash and a runway into 2H 2028. BBI-940, BOLD's first direct ecDNA-targeting asset, is enterin
PRESS RELEASE: NACON announces the temporary suspension of trading in its shares on Euronext Paris
01:30am, Friday, 20'th Feb 2026
Press Release Lesquin, 20 February 2026, 7.30 NACON announces the temporary suspension of trading in its shares on Euronext Paris Lesquin, 20 February 2026, Nacon (the “Company�
Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway
07:00am, Tuesday, 20'th Jan 2026
BBI-940 IND accepted; initiation of first-in-human clinical trial on track for the first half of 2026 Portfolio prioritization, including discontinuation of POTENTIATE trial, extends operating runwa
Boundless Bio Announces Portfolio Prioritization and Runway Extension
04:01pm, Friday, 23'rd May 2025
Portfolio prioritization focuses on novel-novel combination therapy of BBI-355 and BBI-825 and new development candidate, BBI-940, for novel kinesin program
Boundless Bio Announces Pipeline and Leadership Updates
04:01pm, Thursday, 12'th Dec 2024
Company elects not to advance BBI-825 into Part 2 portion of STARMAP clinical trial Third ecDTx program advancing, with plans for development candidate nomination by mid-2025 Operating runway extended
Boundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights
04:01pm, Thursday, 07'th Nov 2024
Enrollment progressing in BBI-355 POTENTIATE and BBI-825 STARMAP clinical trials, with initial proof-of-concept data expected in the second half of 2025
Fresh Tracks Therapeutics Announces Second Adjournment of Special Meeting of Stockholders
05:00pm, Friday, 01'st Dec 2023
Meeting adjourned to December 15, 2023 at 10 a.m. MT
Fresh Tracks Therapeutics Announces Adjournment of Special Meeting of Stockholders
08:30am, Friday, 17'th Nov 2023
Meeting adjourned to November 30, 2023 at 10 a.m. MT Fresh Tracks encourages all stockholders of record on October 17, 2023 who have not yet voted to do so by 11:59 p.m.
Fresh Tracks Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
08:30am, Monday, 13'th Nov 2023
Cash and cash equivalents of approximately $11.5 million as of October 31, 2023 Special meeting of stockholders on November 16 seeking stockholder approval of the Dissolution and Plan of Dissolution
Fresh Tracks Therapeutics Announces Board Approval of Plan of Liquidation and Dissolution
04:01pm, Tuesday, 19'th Sep 2023
Company intends to make cash distributions currently estimated to be between $5 million and $7 million, or $0.84 to $1.17 per share, to shareholders following shareholder approval and the filing of th
Fresh Tracks Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
04:01pm, Friday, 11'th Aug 2023
Strengthened current cash position to approximately $15 million as of July 31, 2023 as a result of sale of future rights to event-based milestone and earnout payments on net sales of sofpironium bro
Fresh Tracks Announces $8.25 Million Buyout of Its Right to Receive Future Sofpironium Bromide Payments from Botanix
08:00am, Friday, 21'st Jul 2023
Strengthens cash position as Company continues to evaluate strategic options to maximize shareholder value Strengthens cash position as Company continues to evaluate strategic options to maximize shar
Fresh Tracks Therapeutics to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 10, 2022
04:05pm, Thursday, 03'rd Nov 2022
BOULDER, Colo., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (“Fresh Tracks Therapeutics” or the “Company”) (Nasdaq: FRTX), a clinical-stage pharmaceutical company aiming
Brickell Biotech Reports Second Quarter 2022 Financial Results and Provides Corporate Update
08:05pm, Thursday, 11'th Aug 2022 GlobeNewswire Inc.
Phase 1 study of BBI-02 progressing well and expect to initiate MAD part of the study next month
